Ronald J Bosch1, Xinyan Zhang, Netanya G Sandler. 1. Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts 02115, USA. rbosch@hsph.harvard.edu
Abstract
PURPOSE OF REVIEW: The dramatic increase in the number and type of immune biomarkers that can be measured, particularly those assessing immune activation, has led to numerous investigations in HIV-infected individuals to explore pathogenesis and to assess therapeutic interventions that aim to attenuate immune activation. An overview is provided on study designs and related statistical and operational issues relevant to these investigations. RECENT FINDINGS: Cohort studies and nested case-control studies within these cohorts have identified multiple biomarkers that are associated with an increased risk of disease. Early-stage clinical trials of therapies to address these risks in HIV-infected individuals with viral suppression on antiretroviral therapy are a substantial focus of current HIV research. SUMMARY: Appropriate study design is essential in biomarker research.
PURPOSE OF REVIEW: The dramatic increase in the number and type of immune biomarkers that can be measured, particularly those assessing immune activation, has led to numerous investigations in HIV-infected individuals to explore pathogenesis and to assess therapeutic interventions that aim to attenuate immune activation. An overview is provided on study designs and related statistical and operational issues relevant to these investigations. RECENT FINDINGS: Cohort studies and nested case-control studies within these cohorts have identified multiple biomarkers that are associated with an increased risk of disease. Early-stage clinical trials of therapies to address these risks in HIV-infected individuals with viral suppression on antiretroviral therapy are a substantial focus of current HIV research. SUMMARY: Appropriate study design is essential in biomarker research.
Authors: Frank O Pettersen; Eirik A Torheim; Anders E A Dahm; Ingeborg S Aaberge; Andreas Lind; Malin Holm; Einar M Aandahl; Per M Sandset; Kjetil Taskén; Dag Kvale Journal: J Virol Date: 2011-04-13 Impact factor: 5.103
Authors: Sheila M Keating; Elizabeth T Golub; Marek Nowicki; Mary Young; Kathryn Anastos; Howard Crystal; Mardge H Cohen; Jinbing Zhang; Ruth M Greenblatt; Seema Desai; Shiquan Wu; Alan L Landay; Stephen J Gange; Philip J Norris Journal: AIDS Date: 2011-09-24 Impact factor: 4.177
Authors: Netanya G Sandler; Handan Wand; Annelys Roque; Matthew Law; Martha C Nason; Daniel E Nixon; Court Pedersen; Kiat Ruxrungtham; Sharon R Lewin; Sean Emery; James D Neaton; Jason M Brenchley; Steven G Deeks; Irini Sereti; Daniel C Douek Journal: J Infect Dis Date: 2011-01-20 Impact factor: 5.226
Authors: Peter W Hunt; Jeffrey N Martin; Elizabeth Sinclair; Lorrie Epling; Juli Teague; Mark A Jacobson; Russell P Tracy; Lawrence Corey; Steven G Deeks Journal: J Infect Dis Date: 2011-05-15 Impact factor: 5.226
Authors: Sara Gianella; Matthew C Strain; Steffney E Rought; Milenka V Vargas; Susan J Little; Douglas D Richman; Celsa A Spina; Davey M Smith Journal: J Virol Date: 2011-11-23 Impact factor: 5.103
Authors: Nikolas Itaru Wada; Lisa P Jacobson; Joseph B Margolick; Elizabeth Crabb Breen; Bernard Macatangay; Sudhir Penugonda; Otoniel Martínez-Maza; Jay H Bream Journal: AIDS Date: 2015-02-20 Impact factor: 4.177
Authors: Jan Wirsching; Sophie Graßmann; Fabian Eichelmann; Laura Malin Harms; Matthew Schenk; Eva Barth; Alide Berndzen; Moses Olalekan; Leen Sarmini; Hedwig Zuberer; Krasimira Aleksandrova Journal: BMC Med Res Methodol Date: 2018-11-06 Impact factor: 4.615